Q3 2022
Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001789769-22-000098
Q3 2022 · 10-Q
Revenue—
Net Income-$56.22M-$56.22M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.43-$0.43 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$56,649,000N/M
Operating Cash Flowderived-$40,877,000N/M
Free Cash Flowderived-$66,076,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|
| Revenue | — | $0.00 | $52.00K |
| Net Income | -$56.22M | -$43.01M | -$7.26M |
| EPS Diluted | -$0.43 | -$0.33 | -$0.43 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Instil Bio, Inc. · CIK 1789769 · Engraved from SEC EDGAR